Our advanced science, patented technologies, and innovative approach to drug discovery and development has allowed us to create and commercialize a portfolio of products that aim to advance the standard of care for acute care and oncology patients.
U.S. FDA approved as a subcutaneous injection
CINVANTI® for CINV:
U.S. FDA approved as both a 30-minute intravenous (IV) infusion and a 2-minute IV injection
ZYNRELEF® for Postoperative Pain Management:
Approved in the U.S., Canada and 31 European Countries
APONVIE™ for Postoperative Nausea and Vomiting (PONV):
U.S. FDA approved as a 30-second IV injection of aprepitant for PONV
Sign-Up for Email Updates
Receive news and updates on Heron’s latest innovations.